Oxford BioMedica To Provide RPR Gencell With Hypoxia Technology
Executive Summary
Rhone-Poulenc Rorer is broadening its relationship with Oxford BioMedica to include a license to the U.K. biotech's hypoxia response element (HRE) gene therapy technology in RPR Gencell's cardiovascular products.
You may also be interested in...
HMR Expands Vertex Deal; Gains U.S. Rights To Arthritis Compound
Hoechst Marion Roussel is expanding its development deal with Vertex for the anti-inflammatory agent HMR 3480/VX-740 to include U.S. marketing rights, the firms said Sept. 1.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011